Getinge came into this Q3 2026 report with a quietly improving story, a 90 day return of about 15.6% and a P/E of 25.5x that sat slightly below both industry and peer averages. The fresh numbers added fuel. Q3 revenue reached SEK 8,446m and net income landed at SEK 719m, backed by an adjusted EBITA margin of 15.1% and strong free cash flow of SEK 1.3b. For a medical equipment group often viewed as a steady compounder rather than a headline grabber, that margin traction is what really challenges old expectations.
Like the margin uplift at Getinge but want more peers with robust profitability and cash generation in the mix? Scan our screener of list of solid balance sheet and fundamentals stocks (203 results) .
Q3 2026 Earnings Summary
-
Revenue (Q3 2026 vs. Q3 2025):SEK 8,446m vs. SEK 8,226m (up 2.7%)
-
Net Income, excl. extra items (Q3 2026 vs. Q3 2025):SEK 719m vs. SEK 566m (up 27.0%)
-
Basic EPS (Q3 2026 vs. Q3 2025):SEK 2.64 vs. SEK 2.08 (up 27.0%)
-
Adjusted EBITA Margin (Q3 2026 vs. Q3 2025):15.1% vs. 13.4% (up 1.7 percentage points)
Earnings grab attention, but investors who care about valuation usually focus on the cash flowing through the business. When you look at Getinge's cash flows instead of just the income line, the stock could be a hefty 39% undervalued .
Recurring Revenue Thesis Meets Margin Reality
Bulls argue that Getinge's richer stream of repeat business should keep earnings quality improving even as markets stay mixed.
"A higher share of recurring and high margin revenue, with around two thirds of sales now recurring and 70% coming from products like ECLS, consumables, infection control and Sterile Transfer, gives Getinge more predictable cash generation that can support earnings quality and net margins."
Q3's 15.1% adjusted EBITA margin, strong free cash flow of SEK 1.3b and low leverage at 1.5x support that story. Life Science capital equipment was soft, yet group profitability held up, which backs the claim that recurring lines now cushion weaker spots.
Quality, Tariffs And China Risks Under The Microscope
The bear side worries that quality fixes, tariffs and China could quietly chip away at that margin progress over the next few years.
"Intensifying global tariffs, particularly between the EU, US and China, are still adding direct costs on top of the already cited SEK 110 million in one quarter. Recent margin progress has also benefited from a one off tariff refund."
Q3 quality costs in Acute Care Therapies remained elevated and margin help from SEK 381m of recent tariff refunds shows why caution persists. China is described as roughly flat with Surgical Workflows under pressure, and Life Science capital demand was weak, so some growth and leverage constraints are still visible.
The price and this Narrative do not agree. → Uncover what this Narrative says Getinge is actually worth .
Hunt For Quiet Margin Stories
Getinge just showed how recurring revenue and disciplined costs can shift an earnings story without a dramatic share price move. The real opportunity is spotting stocks that could be undervalued before stronger fundamentals are fully recognised.
-
Company 1 - 31% below our estimate - targets higher margin work by tightening its portfolio and realigning plants to support aftermarket demand for critical flow equipment.
-
Company 2 - 32% below our estimate - shifts focus toward higher value industrial bearings and carves out its lower margin automotive arm through cost cuts and structural separation.
-
Company 3 - 24% below our estimate - builds out copper projects that expand output and add polymetallic by product exposure after permits and mine development milestones are met.
Those are three of them. See all 190 potentially undervalued companies →
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include GETI-B.ST .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
